Human medicines European public assessment report (EPAR): Pregabalin Sandoz, pregabalin, Date of authorisation: 19/06/2015, Revision: 23, Status: Authorised

Human medicines European public assessment report (EPAR): Izamby, denosumab, Date of authorisation: 26/06/2025, Revision: 2, Status: Authorised

Human medicines European public assessment report (EPAR): Mysildecard, sildenafil, Date of authorisation: 15/09/2016, Revision: 10, Status: Authorised

Human medicines European public assessment report (EPAR): Krazati, adagrasib, Date of authorisation: 05/01/2024, Revision: 3, Status: Authorised

Human medicines European public assessment report (EPAR): Upstaza, eladocagene exuparvovec, Date of authorisation: 18/07/2022, Revision: 9, Status: Authorised

Opinion/decision on a Paediatric investigation plan (PIP): Ilumetri, tildrakizumab, decision type: P: decision agreeing on a investigation plan, with or without partial waiver(s) and or deferral(s), therapeutic area: Musculoskeletal and connective tissue disorders, PIP number: P/0388/2024

Opinion/decision on a Paediatric investigation plan (PIP): Ultomiris, ravulizumab, decision type: P: decision agreeing on a investigation plan, with or without partial waiver(s) and or deferral(s), therapeutic area: Renal and urinary disorders, PIP number: P/0387/2024

Opinion/decision on a Paediatric investigation plan (PIP): Spevigo, spesolimab, decision type: PM: decision on the application for modification of an agreed PIP, therapeutic area: Congenital, familial and genetic disorders, PIP number: EMA/PE/0000232315

Committee for Medicinal Products for Veterinary Use (CVMP): 2-4 December 2025, European Medicines Agency, Amsterdam, the Netherlands, from 2 December 2025 to 4 December 2025

Agenda of the CVMP meeting 2-4 December 2025